Hot or Not, Stock Market Edition: 04/17/2025

Here’s what’s hot (and what’s not) in the market right now:

• HOT: Analysts are bullish on Nutanix (NASDAQ: NTNX); Atlassian (NASDAQ: TEAM) rises following a prominent new hire
• NOT: Summit Therapeutics (NASDAQ: SMMT) loses after a big run last week; EV companies like XPeng (NYSE: XPEV) continue to feel pain in the current market

P.S. For more stocks making moves, check out our new Zen Ratings Upgrades & Downgrades screener.

🔥 HOT: Nutanix (NASDAQ: NTNX) is a big data storage company that analysts are bullish on right now. It gained 4.1% on Tuesday as the market continues to digest the company’s announcement of a new cost-effective storage model aimed at big businesses. The program, which is called the Enterprise Volume Agreement, is designed to help enterprise-scale businesses with their ever-increasing data storage needs. Our research gives the stock an A rating in Growth and B ratings in Sentiment and Financials. The stock is slightly volatile but not much more than your typical growth tech stock. Our quant rating system gives the company a Zen Rating of A and a Strong Buy recommendation.

🥶 NOT: Summit Therapeutics (NASDAQ: SMMT) lost 5.8% on Tuesday, giving back some of the 47.1% it gained since Friday. The company’s stock price soared after its CEO, Bob Duggan, exercised options early to acquire a staggering four million shares. Analysts at Cantor Fitzgerald covered this news and triggered a rally by emphasizing the bullish picture this paints for the company’s future. We’re not as enthusiastic about SMMT as some people since we find biopharmaceutical stocks to be a bit too swingy for our tastes. Still, we give SMMT a C Zen Rating and a Hold recommendation.

🔥 HOT: Shares of Atlassian (NASDAQ: TEAM) gained 3.1% on Tuesday after naming former AOL CFO Karen Dykstra to its board of directors. TEAM has fallen along with the rest of the Nasdaq this year, losing 15.3% YTD as of Tuesday’s close. While momentum is not on its side, our analysis suggests that TEAM is poised for growth when the market inevitably recovers. Our component analysis gives the stock a strong A rating in Growth and a solid B in Financials. Overall, we give TEAM a B Zen Rating and a Buy recommendation.

🥶 NOT: Chinese EV manufacturer XPeng (NYSE: XPEV) lost 6.0% on Tuesday as the trade war between China and the U.S. continued. The Tesla competitor has recently gained ground in China but lost favor in the U.S. as auto and chip tariffs make its future uncertain. The company has a B rating in Sentiment but D ratings in Value and Financials, giving it a C Zen Rating and a Hold recommendation for now. XPEV doesn’t report earnings until May 27th, but Tesla’s (NASDAQ: TSLA) report on April 22nd could have an impact on it.

What to Do Next?

• 200 Stocks to Sell Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.